孟鲁司特钠联合丙酸氟替卡松雾化吸入治疗咳嗽变异性哮喘患儿的疗效分析

Efficacy Analysis of Fluticasone Propionate Nebulized Inhalation in the Treatment of Cough Variant Asthma in Chil⁃dren

目的:探讨与分析孟鲁司特钠联合丙酸氟替卡松雾化吸入治疗咳嗽变异性哮喘(CVA)患儿的临床疗效。方法:选取2021年1月—2022年12月扬州市江都人民医院收治的CVA患儿共计74例作为研究对象,利用随机抽签法分组,将患儿平均分成两组,每组各37例。对照组患儿给予丙酸氟替卡松雾化吸入治疗,研究组患儿在此基础上给予孟鲁司特钠咀嚼片治疗,两组患儿治疗观察12周,记录患儿的预后情况。结果:治疗12周后,研究组患儿符合治疗有效标准的共计36例,占比为97.30%,对照组30例,占比为81.08%,研究组患儿治疗的总有效率高于对照组,差异有统计学意义(χ^(2)=5.045,P<0.05)。治疗12周后,研究组患儿日间、夜间咳嗽症状评分与对照组相比明显降低,差异均有统计学意义(t=25.927、10.976,P<0.05)。治疗12周后,两组患儿最大呼气流速(PEF)、第1秒用力呼气量(FEV1)都高于治疗前,差异均有统计学意义(t=5.542、8.324,P<0.05)。研究组患儿治疗12周期间的头痛、腹痛、眩晕、声音嘶哑等不良反应发生率为5.41%,低于对照组的10.81%,差异有统计学意义(χ^(2)=4.163,P<0.05)。结论:孟鲁司特钠联合丙酸氟替卡松雾化吸入治疗咳嗽变异性哮喘患儿能够提高治疗效果,缓解患儿的日间与夜间咳嗽症状,也可改善患儿的肺功能,且安全性较高。

Objective:To explore and analyze the efficacy of montelukast sodium combined with fluticasone propionate nebulized inhalation in the treatment of children with cough variant asthma.Methods:74 children with cough variant asthma admitted to Jiangdu People’s Hospital in Yangzhou City for treatment were collected for the study from January 2021 to December 2022.The children were divided into two groups by random drawing,with 37 cases in each group.The control group was treated with nebulized inhalation of fluticasone propionate,while the study group was treated with montelukast sodium chewable tablets.Both the study group and the control group were treated and observed for 12 weeks,and the prognosis of the children was recorded.Results:After 12 weeks of treatment,a total of 36 cases(97.30%)in the study group met the effective treatment criteria,while the control group had only 30 cases(81.08%).The total effective rate of the study group was more prominent and better than that of the control group(χ^(2)=5.045,P<0.05).The daytime and nighttime cough symptom scores of the study group after 12 weeks of treatment were also significantly lower than those of the control group(t=25.927,10.976;P<0.05).The maximum expiratory flow rate and forced expiratory volume in the first second after 12 weeks of treatment in both groups were higher than before treatment(t=5.542,8.324;P<0.05).The incidence of adverse reactions,such as headache,abdominal pain,dizziness,and hoarseness during the 12 cycles of treatment in the study group was 5.41%,compared with 10.81%in the control group.There was no difference between the study group and the control group(χ^(2)=4.163,P>0.05).Conclusion:The combination of montelukast sodium and fluticasone propionate nebulized inhalation can improve the treatment effect,alleviate daytime and nighttime cough symptoms,and improve lung function in children with cough variant asthma,with relatively high safety.